Checkpoint Therapeutics, Inc.

( )
CKPT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -0.23%182.090.7%$1408.23m
PFEPfizer Inc. -0.17%51.610.9%$1232.04m
MRKMerck & Co., Inc. -0.81%92.520.7%$1231.41m
BMYBristol-Myers Squibb Co. -0.17%78.861.0%$1135.54m
LLYEli Lilly & Co. -0.10%325.351.1%$1134.85m
ABBVAbbVie, Inc. -0.04%152.491.9%$1018.85m
AZNAstraZeneca Plc -0.63%66.481.0%$449.25m
SGENSeagen Inc. -1.61%176.455.7%$320.77m
GSKGSK Plc -0.44%43.500.2%$296.14m
TPTXTurning Point Therapeutics, Inc. 0.00%75.170.0%$291.93m
MRTXMirati Therapeutics, Inc. 2.70%70.001.6%$204.79m
SIGASIGA Technologies, Inc. -10.81%11.630.0%$195.93m
HZNPHorizon Therapeutics Plc 0.00%85.135.4%$182.59m
NVSNovartis AG -0.04%84.790.2%$167.69m
NVONovo Nordisk A/S 0.58%112.820.1%$148.21m

Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.